High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 401–500 of 1,000
Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis
Kagoya, Y., Nannya, Y., & Kurokawa, M. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.04.001 · Cited by 49
Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Hayman, S. R., Buadi, F. K., & Hogan, W. J. (2010) · Blood · doi:10.1182/blood-2009-07-235531 · Cited by 48
Kharfan‐Dabaja, M. A., Hamadani, M., Reljic, T., Nishihori, T., Bensinger, W., Djulbegović, B., & Kumar, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-2 · Cited by 50
“Discussion Auto-HCT has been regarded as the standard of care for younger myeloma patients [1,23].”
BackgroundWang, X., Sinn, A. L., Pollok, K. E., Sandusky, G. E., Zhang, S., Chen, L., Liang, J., Crean, C., Suvannasankha, A., Abonour, R., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08248.x · Cited by 50
“While highdose chemotherapy with stem cell support increases the proportion of complete responses, the effect on overall survival remains relatively modest, and all patients invariably relapse (Attal et al, 1996, 2003; Riccardi et al, 2000; Child et al, 2003).”
BackgroundGabriel, I. H., Sergeant, R., Szydlo, R., Apperley, J. F., deLavallade, H., Alsuliman, A., Khoder, A., Marín, D., Kanfer, E., Cooper, N., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273706 · Cited by 52
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
Qazilbash, M., Saliba, R. M., Hosing, C. M., Mendoza, F. L., Qureshi, S. R., Weber, D. M., Wang, M., Flosser, T., Couriel, D. R., Lima, M. J. G. D., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705580 · Cited by 50
Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
Richardson, P. G. G., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8851 · Cited by 48
“The advent of high-dose therapy and autologous peripheral blood stem cell transplantation as an effective treatment modality for younger multiple myeloma patients necessitated the development of initial therapy, that minimized alkylator exposure to facilitate successful stem cell collection.(3,4) The combination of vi…”
BackgroundBendamustine in patients with relapsed or refractory multiple myeloma
Michael, M., Bruns, I., Bölke, E., Zohren, F., Czibere, A. G., Safaian, N., Neumann, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-1-13 · Cited by 47
Multiple myeloma – current issues and controversies
Kumar, S. K. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70006-2 · Cited by 53
Wannesson, L., Panzarella, T., Mikhael, J., & Keating, A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm069 · Cited by 49
“Randomized trials show improved overall survival for autotransplants over standard chemotherapy in patients with relapsed intermediate or high-grade non-Hodgkin’s lymphoma (NHL) [1, 2] and multiple myeloma [3, 4].”
BackgroundHow I treat the young patient with multiple myeloma
Gandolfi, S., Prada, C. P., & Richardson, P. G. G. (2018) · Blood · doi:10.1182/blood-2017-05-693606 · Cited by 56
Alvares, C. L., Davies, F. E., Horton, C., Patel, G. W., Powles, R., Sirohi, B., Zuha, R., Gatt, A., Saso, R. M., Treleaven, J. G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05514.x · Cited by 49
“In total, 50% of patients receiving HDM achieved a CR (Fig 1), which compares favourably with other published series (Attal et al, 1996; Davies et al, 2001; Child et al, 2003).”
ResultSelf-citationKühne, A., Tzvetkov, M. V., Hagos, Y., Lage, H., Burckhardt, G., & Brockmöller, J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.03.026 · Cited by 47
Khong, T. T., Sharkey, J., & Spencer, A. (2008) · Haematologica · doi:10.3324/haematol.12261 · Cited by 51
“0 years.(3,4) Furthermore, the introduction of bisphosphonates as a standard component of supportive care in the prevention of osteolysis has reduced the likelihood of skeletal-related morbidity and may have enhanced survival in subgroups of patients.”
BackgroundBrinker, B. T., Waller, E. K., Leong, T. L., Heffner, L. T., Redei, I., Langston, A. A., & Lonial, S. (2006) · Cancer · doi:10.1002/cncr.21852 · Cited by 50
“32 Partial response 19 (38) 20 (39) Stable 3 (6) 8 (16) Progression 13 (26) 8 (16) Data not available 4 7”
Maier, P., Spier, I., Laufs, S., Veldwijk, M. R., Früehauf, S., Wenz, F. K., & Zeller, W. J. (2009) · Gene Therapy · doi:10.1038/gt.2009.133 · Cited by 50
Gay, F., Oliva, S., Petrucci, M. T., Montefusco, V., Conticello, C., Musto, P., Catalano, L., Evangelista, A., Spada, S., Campbell, P. J., et al. (2016) · Leukemia · doi:10.1038/leu.2016.381 · Cited by 49
González‐Calle, V., Cerdá, S., Labrador, J., Sobejano, E., González-Mena, B., Aguilera, C., Ocio, E. M., Vídriales, M., Puig, N., Gutierrez, N. C., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.158345 · Cited by 52
Role of Stem Cell Transplantation in Multiple Myeloma
Devarakonda, S. S., Efebera, Y. A., & Sharma, N. (2021) · Cancers · doi:10.3390/cancers13040863 · Cited by 48
“MRC VII [52] Intensive therapy (VCAP) vs.”
BackgroundHaplotypes in the tumour necrosis factor region and myeloma
Morgan, G. J., Adamson, P. J., Mensah, F. K., Spink, C. F., Law, G. R., Keen, L. J., Roman, E., Davies, F. E., Rollinson, S. J., Child, J. A., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05467.x · Cited by 50
“A total of 181 participants from the Medical Research Council (MRC) Myeloma VII trial (Child et al, 2003), were included in the analysis.”
BackgroundSelf-citationNew therapies in multiple myeloma
Merchionne, F., Perosa, F., & Dammacco, F. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0134-y · Cited by 50
Burzynski, J. A., Toro, J. J., Patel, R. C., Lee, S., Greene, R. E., Ochoa-Bayona, J. L., Frei, C. R., & Freytes, C. O. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903085936 · Cited by 48
“Randomized, controlled trials have demonstrated that autologous stem cell transplant prolongs disease-free and overall survival (OS) in patients with multiple myeloma (MM) [1,2].”
BackgroundProteasome inhibitor, bortezomib, for myeloma and lymphoma
Tobinai, K. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0695-5 · Cited by 50
Amadori, S., Fenaux, P., Ludwig, H., O'Dwyer, M. E., & Sanz, M. Á. (2005) · Current Medical Research and Opinion · doi:10.1185/030079904x20349 · Cited by 46
Dimopoulos, M. A., Anagnostopoulos, A., Terpos, E., Repoussis, P., Zomas, A., Katodritou, E., Kyrtsonis, M. C., Delibasi, S., Vassou, A., Pouli, A. G., et al. (2006) · PubMed · Cited by 48
Wu, P., Davies, F. E., Horton, C., Jenner, M. W., Krishnan, B., Alvares, C. L., Saso, R. M., Mccormack, R., Dines, S., Treleaven, J. G., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600821955 · Cited by 49
“High-dose therapy with PBSCT has been considered as the standard of care for eligible patients with newly diagnosed myeloma for last decade [11,12].”
BackgroundSelf-citationA review of the proteasome inhibitor bortezomib in multiple myeloma
Richardson, P. G. G. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.6.1321 · Cited by 50
“Although some modalities, such as autologous stem cell transplantation (SCT) following high-dose therapy, have improved response and survival compared with that achieved with standard chemotherapy [4,5], MM remains incurable; relapse with drug-resistant disease inevitably occurs [3,6,7].”
BackgroundHaplotypic structure across the IκBα gene (NFKBIA) and association with multiple myeloma
Spink, C. F., Gray, L. C., Davies, F. E., Morgan, G. J., & Bidwell, J. L. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.02.001 · Cited by 49
Self-citationKebriaei, P., Madden, T. L., Kazerooni, R., Wang, X., Thall, P. F., Ledesma, C., Nieto, Y. L., Shpall, E. J., Hosing, C. M., Qazilbash, M. H., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.07.016 · Cited by 45
“1 months.[41] We reported data from our center with Mel 200 mg/m2 for a single autologous transplant that showed an overall response rate of 69% and median PFS of 20 months[42].”
BackgroundAbonour, R., Wagner, L. I., Durie, B. G. M., Jagannath, S., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Kitali, A., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3446-y · Cited by 46
Kumar, L., Ramavath, D., Kataria, B., Tiwari, A., Raj, A., Chellapuram, S. K., Mookerjee, A., Sahoo, R., Malik, P. S., Sharma, A., et al. (2019) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1593_18 · Cited by 45
Bair, S. M., Brandstadter, J. D., Ayers, E. C., & Stadtmauer, E. A. (2020) · Cancer · doi:10.1002/cncr.32659 · Cited by 51
The impact of race on outcomes of autologous transplantation in patients with multiple myeloma
Verma, P. S., Howard, R. S., & Weiss, B. M. (2008) · American Journal of Hematology · doi:10.1002/ajh.21139 · Cited by 45
Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial
Qazilbash, M. H., Saliba, R. M., Nieto, Y. L., Parikh, G. C., Pelosini, M., Khan, F. B., Jones, R. B., Hosing, C. M., Mendoza, F. L., Weber, D. M., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.09.019 · Cited by 47
Management of multiple myeloma in Asia: resource-stratified guidelines
Tan, D. C. L., Chng, W. J., Chou, T., Nawarawong, W., Hwang, S.-Y., Chim, C. S., Chen, W.-M., Durie, B. G. M., & Lee, J. H. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70404-2 · Cited by 51
Landgren, O., & Owen, R. G. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21273 · Cited by 44
“with a smaller proportion achieving sCR (6,7).”
Self-citationPlerixafor: A Peripheral Blood Stem Cell Mobilizer
Knable, M. K., Gatesman, M. L., & Kockler, D. R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.5.485 · Cited by 44
Auner, H. W., Szydlo, R., Rone, A., Chaidos, A., Giles, C. M., Kanfer, E., Macdonald, D. H. C., Marín, D., Milojković, D., Pavlů, J., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.773998 · Cited by 45
Kastritis, E., Ρούσσου, Μ., Eleutherakis‐Papaiakovou, E., Gavriatopoulou, M., Migkou, M., Gika, D., Fotiou, D., Kanellias, N., Ziogas, D. C., Ntanasis‐Stathopoulos, I., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.10.014 · Cited by 46
Feyler, S., Rawstron, A. C., Jackson, G. H., Snowden, J. A., Cocks, K., & Johnson, R. J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06817.x · Cited by 45
“High-dose melphalan-based autografting (HDM) is a standard of care, results in good disease control and increases median survival (Child et al, 2003).”
BackgroundGrövdal, M., Nahi, H., Gahrton, G., Liwing, J., Waage, A., Abildgaard, N., Pedersen, P. T., Hammerstrøm, J., Laaksonen, A.-L., Bazia, P., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.39 · Cited by 46
Medical management update: Multiple myeloma
Stoopler, E. T., Vogl, D. T., & Stadtmauer, E. A. (2007) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.10.026 · Cited by 50
Fenk, R. R., Michael, M., Zohren, F., Graef, T. T., Czibere, A. G., Bruns, I., Neumann, F., Fenk, B., Haas, R. R., & Kobbe, G. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701694194 · Cited by 46
“High dose chemotherapy followed by autologous peripheral blood stem cell transplantation has improved response rates and survival in patients with multiple myeloma [1,2].”
BackgroundSharma, M. R., Khan, H. M., Thall, P. F., Orlowski, R. Z., Bassett, R. L., Shah, N. D., Bashir, Q., Parmar, S., Wang, M. L., Shah, J. J., et al. (2011) · Cancer · doi:10.1002/cncr.26517 · Cited by 46
“Several large clinical trials have demonstrated the safety and efficacy of bortezomib in MM.9-11 In vitro exposure of DOI: 10.1002/cncr.26517, Received: June 8, 2011; Revised: July 27, 2011; Accepted: July 28, 2011, Published online September 1, 2011 in Wiley Online Library (wileyonlinelibrary.com) Corresponding autho…”
BackgroundInfluentialRoyston, D. J., Gao, Q., Nguyen, N., Maslak, P. G., Doǧan, A., & Roshal, M. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw052 · Cited by 46
“Multiple myeloma (MM) remains a largely incurable disease despite improvements in the progression-free survival (PFS) and overall survival (OS) following the advent of high-dose melphalan and autologous stem cell transplantation (ASCT).(1) However, with the advent of novel first-line therapies such as immunomodulatory…”
BackgroundMoreb, J. S., Byrne, M. T., Shugarman, I. L., Zou, F., Xiong, S., May, W. S., Norkin, M., Hiemenz, J., Brown, R., Cogle, C. R., et al. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21556 · Cited by 46
Treatment of plasma cell dyscrasias with lenalidomide
Dimopoulos, M. A., Kastritis, E., & Rajkumar, S. V. (2008) · Leukemia · doi:10.1038/leu.2008.123 · Cited by 45
Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma
Kuruvilla, J. G., Shepherd, J. D., Sutherland, H. J., Nevill, T. J., Nitta, J. Y., Le, A., Forrest, D. L., Hogge, D. E., Lavoie, J. C., Nantel, S. H., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.04.006 · Cited by 47
“Although the survival benefit of ASCT r ompared to conventional chemotherapy is in dispute, he relatively low morbidity and mortality rate make it n attractive therapeutic modality [1-5].”
BackgroundMultiple myeloma: New staging systems for diagnosis, prognosis and response evaluation
Rajkumar, S. V., & Buadi, F. K. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.10.002 · Cited by 47
Relationship Between Depth of Response and Outcome in Multiple Myeloma
Dingli, D., Pacheco, J. M., Nowakowski, G. S., Kumar, S. K., Dispenzieri, A. A., Hayman, S. R., Lacy, M. Q., Gastineau, D. A., & Gertz, M. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7879 · Cited by 45
Perspectives for combination therapy to overcome drug-resistant multiple myeloma
Catley, L. P., Tai, Y., CHAUHAN, D., & Anderson, K. C. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.06.001 · Cited by 44
Prince, H. M., Simmons, P. J., Whitty, G. A., Wall, D. P., Barber, L., Toner, G. C., Seymour, J. F., Richardson, G. E., Mrongovius, R. I., & Haylock, D. N. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05081.x · Cited by 47
“…(HDT) supported by autologous bone marrow or peripheral blood progenitor cells (PBPC) achieve higher response rates than conventional-dose chemotherapy and this translates into improved disease-free and overall survival (Philip et al, 1995; Linch et al, 1993; Attal et al, 1996; Child et al, 2003).”
BackgroundMartino, M. V., Praticò, G., Messina, G., Irrera, G., Massara, E., Messina, G., Console, G., & Iacopino, P. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00736.x · Cited by 47
Singhal, S., & Mehta, J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03060906 · Cited by 56
Cheng, J., Schmitt, M. W., Wuchter, P., Buss, E. C., Witzens‐Harig, M., Neben, K., Hundemer, M., Hillengaß, J., Alexi, R., Goldschmidt, H., et al. (2014) · Transfusion · doi:10.1111/trf.12813 · Cited by 47
“Parameter CD34+ < 20 × 10(6)/L PB CD34+ ≥ 20 × 10(6)/L PB Group A1, plerixafor Group A2, no plerixafor Group B1, plerixafor Group B2, no plerixafor Number of patients 11 11 12 12 Age (years)* 65 (61-73) 63 (47-71) 61 (40-67) 61 (46-72) Sex (male:female) 7:4 7:4 7:5 9:3 Previous CTx cycles* 3 (1-8) 4 (3-25) 3 (2-7) 3 (…”
Tsai, S. B., Seldin, D. C., Quillen, K., Berk, J. L., Ruberg, F. L., Meier-Ewert, H. K., Sloan, J. M., Doros, G. D., Finn, K. T., Skinner, M. M., et al. (2012) · Blood · doi:10.1182/blood-2012-09-457341 · Cited by 42
Second autologous transplant as salvage therapy in multiple myeloma
Atanackovic, D., & Schilling, G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12579 · Cited by 45
“…all patients who have received an initial ASCT will relapse with most of them showing progressive disease after a median of 21–39 months (Attal et al, 1996, 2003; Child et al, 2003; Alvares et al, 2006; Blimark et al, 2011; Jimenez-Zepeda et al, 2012; Auner et al, 2013; Gonsalves et al, 2013).”
BackgroundGeorges, G. E., Maris, M. B., Maloney, D. G., Sandmaier, B. M., Sorror, M. L., Shizuru, J. A., Lange, T., Agura, E. D., Bruno, B., McSweeney, P. A., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.11.011 · Cited by 45
Tariman, J. D., Doorenbos, A. Z., Schepp, K. G., Becker, P. S., & Berry, D. L. (2014) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2014.08.003 · Cited by 46
“HDT using high-dose intravenous melphalan followed by autologous HSCT is considered an important treatment option for MM patients under the age of 65 [46–48].”
MethodMaintenance therapy in multiple myeloma
Mihelic, R. A., Kaufman, J., & Lonial, S. (2007) · Leukemia · doi:10.1038/sj.leu.2404633 · Cited by 44
Stem-cell transplantation in multiple myeloma
Harousseau, J., Moreau, P., Attal, M., Facon, T. T. F., & Avet‐Loiseau, H. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.005 · Cited by 42
Nooka, A. K., Kaufman, J. L., Behera, M., Langston, A. A., Waller, E. K., Flowers, C. R., Gleason, C. L., Boise, L., & Lonial, S. (2013) · Cancer · doi:10.1002/cncr.28325 · Cited by 47
“4% at 3 y 86% at 3 y 84% at 3 y 72% at 4 y 65% at 4 y 61% at 5 y 55% at 5 y Grade 3 toxicities Anemia 10 (4) 21 (9) 8 (2) 7 (2) Neutropenia 12 (5) 24 (10) 42 (16) 18 (14) 3 (1) 1 (0) Thrombocytopenia 7 (3) 3 (1) 18 (7) 6 (5) 10 (2) 5 (1) Infections 21 (9) 29 (12) 7 (3) 11 (5) 47 (18) 21 (16) 26 (6) 21 (5) VZV reactiva…”
Management of paraproteinaemia
Cook, L. B. M., & Macdonald, D. H. C. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.054627 · Cited by 52
Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma
Shah, S. R., & Tran, T. M. (2007) · Drugs · doi:10.2165/00003495-200767130-00005 · Cited by 46
Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp140 · Cited by 43
High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma
Wildes, T. M., Finney, J. D., Fiala, M. A., Gao, F., Vij, R., Stockerl-Goldstein, K. E., Carson, K. R., Mikhael, J., & Colditz, G. A. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.106 · Cited by 43
“(5) In randomized trials, high dose therapy with autologous stem cell transplantation (ASCT) prolongs survival in patients with MM, compared to conventional chemotherapy.(6,7) However, these studies specifically excluded patients over the age of 65, with a median age of enrolled patients of 55–57 years.”
BackgroundSchmidt‐Hieber, M., Blau, I. W., Trenschel, R., Andreesen, R., Stuhler, G., Einsele, H., Kanz, L., Keilholz, U., Marinets, O., Beelen, D. W., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705605 · Cited by 41
Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma
Eucker, J., Baengeroth, K., Zavrski, I., Krebbel, H., Zang, C., Heider, U., Jakob, C., Elstner, E., Possinger, K., & Sezer, O. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200411000-00004 · Cited by 45
Tinguely, M., Jenni, B., Knights, A. J., Lopes, B., Korol, D., Rousson, V., Fontecedro, A. C., Cogliatti, S., Bittermann, A. G., Schmid, U., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00738.x · Cited by 41
Clinical impact of chromosomal aberrations in multiple myeloma
Nahi, H., Sütlü, T., Jansson, M., Alici, E., & Gahrton, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02324.x · Cited by 43
Muta, T., Miyamoto, T., Fujisaki, T., Ohno, Y., Kamimura, T., Kato, K., Takenaka, K., Iwasaki, H., Eto, T., Takamatsu, Y., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8390 · Cited by 41
Reece, D. E., Vesole, D. H., Shrestha, S., Zhang, M., Pérez, W. S., Dispenzieri, A. A., Milone, G., Abidi, M. H., Atkins, H. L., Bashey, A., et al. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.078 · Cited by 40
“Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.”
BackgroundSweiss, K. I., Patel, S., Culos, K., Oh, A. L., Rondelli, D., & Patel, P. R. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.136 · Cited by 41
The evolution of stem-cell transplantation in multiple myeloma
Mahajan, S., Tandon, N., & Kumar, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718761776 · Cited by 44
Dhakal, B., Shah, N. D., Kansagra, A. J., Kumar, A., Lonial, S., Garfall, A. L., Cowan, A. J., Poudyal, B. S., Costello, C. L., Gay, F., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.019 · Cited by 46
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
Dimopoulos, M. A., Souliotis, V. L., Anagnostopoulos, Α., Bamia, C., Pouli, A. G., Baltadakis, I., Terpos, E., Kyrtopoulos, S. Α., & Sfikakis, P. P. (2007) · Haematologica · doi:10.3324/haematol.11435 · Cited by 44
Myeloma in the Real World: What Is Really Happening?
Bergin, K., McQuilten, Z., Moore, E., Wood, E. M., & Spencer, A. G. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.12.002 · Cited by 42
Costa, L. J., Nista, E., Buadi, F. K., Lacy, M. Q., Dispenzieri, A. A., Kramer, C., Edwards, K. H., Kang, Y., Gertz, M. A., Stuart, R. K., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.003 · Cited by 42
Advanced prostate cancer—a case for adjuvant differentiation therapy
Rane, J. K., Pellacani, D., & Maitland, N. J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.157 · Cited by 43
Belotti, A., Ribolla, R., Cancelli, V., Crippa, C., Bianchetti, N., Ferrari, S., Bottelli, C., Cattaneo, C. M., Tucci, A., Barrigon, C. D. L. F., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25797 · Cited by 43
“Autologous stem cell transplantation (ASCT) is considered the preferred treatment for eligible patients with multiple myeloma (MM) under the age of 65, according to the results of large randomized clinical trials.(1,2) ASCT has also been shown to be feasible and effective in selected older patients.”
BackgroundRole of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 43
Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
Morè, S., Corvatta, L., Manieri, V. M., Saraceni, F., Scortechini, I., Mancini, G., Fiorentini, A., Olivieri, A., & Offidani, M. (2022) · Cells · doi:10.3390/cells11040606 · Cited by 44
Uy, G. L., Costa, L. J., Hari, P., Zhang, M.-J., Huang, J.-X., Anderson, K. C., Bredeson, C., Callander, N. S., Cornell, R. F., Perez, M. A. D., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.190 · Cited by 43
Sánchez‐Ortega, I., Querol, S., Encuentra, M., Ortega, S., Serra, A., Sánchez-Villegas, J., Grífols, J.-R., Pujol-Balaguer, M. M., Pujol-Bosch, M., Martí, J. M., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.196 · Cited by 39
Jalili, A., Ozaki, S., Hara, T., Shibata, H., Hashimoto, T., Abe, M., Nishioka, Y., & Matsumoto, T. (2005) · Blood · doi:10.1182/blood-2005-04-1438 · Cited by 39
Kayal, S., Sharma, A., Iqbal, S., Tilak, T., Cyriac, S. L., & Raina, V. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.09.001 · Cited by 41
Barlogie, B., Anaissie, E. J., van Rhee, F., Shaughnessy, J. D., Szymonifka, J. D., Hoering, A., Petty, N. M., & Crowley, J. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4465 · Cited by 39
Stem Cell Transplantation for Multiple Myeloma: Current and Future Status
Giralt, S. (2011) · Hematology · doi:10.1182/asheducation-2011.1.191 · Cited by 41
(KMMWP), K. M. M. W. P., Jung, S., Cho, M.-S., Kim, H. K., Kim, S. J., Kım, K., Cheong, J., Kim, S., Kim, J. S., Ahn, J., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2645-y · Cited by 44
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
Volpin, V., Michels, T., Sorrentino, A., Menevse, A. N., Knoll, G., Ditz, M., Milenkovic, V. M., Chen, C.-Y., Rathinasamy, A., Griewank, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0608 · Cited by 41
Pawlyn, C., Cairns, D. A., Menzies, T., Jones, J. R., Jenner, M. W., Cook, G., Boyd, K. D., Drayson, M. T., Kaiser, M., Owen, R. G., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.262360 · Cited by 44
“haematologica | 2022; 107(1) 239 Figure 3.”
InfluentialSelf-citationKaur, G., Saldarriaga, M. M., Shah, N. N., Catamero, D., Yue, L., Ashai, N., Goradia, N., Heisler, J., Xiao, Z., Ghalib, N., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.013 · Cited by 39
Ragon, B. K., Shah, M. V., D’Souza, A., Estrada‐Merly, N., Gowda, L., George, G., Lima, M. J. G. D., Hashmi, S. K., Kharfan‐Dabaja, M. A., Majhail, N. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009138 · Cited by 38
Velikova, G., Weis, J., Hjermstad, M. J., Kopp, M., Morris, P., Watson, M., & Sezer, O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.004 · Cited by 42
Berenson, J. R., Yang, H. H., Vescio, R. A., Nassir, Y., Mapes, R., Lee, S.-P., Wilson, J., Yellin, O., Morrison, B., Hilger, J., et al. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0501-0 · Cited by 38
“Over the past decade, high-dose chemotherapy followed by autologous stem cell transplantation (HDTASCT) has demonstrated improved survival (54 months compared to 42 months for standard therapy) [4] and has become the standard of care for newly diagnosed patients aged 65 or younger [4–6].”
BackgroundHan, Y., Zhang, S., Wu, J., Kang, Y., Zhang, Y., Lihui, Y., & Bi, L. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.488708 · Cited by 38
“High-dose therapy plus autologous stem cell transplant has achieved higher complete response rates than conventional chemotherapy, but in the long run most patients relapse [4].”
BackgroundExtramedullary plasmacytoma of the small intestine: Clinical features, diagnosis and treatment
da Silva, R. L. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00544.x · Cited by 37
Cho, Y., Sborov, D., Lamprecht, M., Li, J., Wang, J., Hade, E. M., Gao, Y., Tackett, K., Williams, N. O., Benson, D., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.644 · Cited by 40
Multiple myeloma: chemotherapy or transplantation in the era of new drugs
Palumbo, A., & Rajkumar, S. V. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01431.x · Cited by 39
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone
Sung, A. D., Grima, D. T., Bernard, L. M., Brown, S. L., Carrum, G., Holmberg, L., Horwitz, M. E., Liesveld, J. L., Kanda, J., McClune, B. L., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.80 · Cited by 37
“In patients with relapsed lymphoma or multiple myeloma in first or second remission, it can improve progression free survival as well as overall survival 1–4 .”
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.